Investigational Drug Z-Basivarsen Shows Sustained Strength and Function Gains in Myotonic Dystrophy
Phase I/II trial data show z-basivarsen delivers lasting motor and strength improvements in adults with myotonic dystrophy type 1 over 12 months.
Summary
Myotonic dystrophy type 1 (DM1) is a progressive genetic muscle disease with no approved disease-modifying treatment. New data from the ACHIEVE trial suggest that z-basivarsen, an investigational antisense drug, meaningfully improves muscle function and strength in adults with DM1. Over 12 months, 26 patients showed sustained reductions in hand myotonia, better sit-to-stand performance, and improved muscle strength scores compared to untreated patients following the natural disease course. The drug works by targeting toxic RNA buildup caused by a DMPK gene mutation that disrupts normal protein production in muscle. Safety appeared acceptable, with no serious drug-related adverse events. While still in early-phase trials, these findings represent a potentially significant step toward a first-ever disease-modifying therapy for a condition that typically robs adults in their prime of muscle control and functional independence.
Detailed Summary
Myotonic dystrophy type 1 is the most common adult-onset muscular dystrophy, caused by a mutation in the DMPK gene that floods cells with toxic RNA, disrupting the splicing of proteins essential for normal muscle function. Symptoms typically emerge between ages 20 and 40, progressively stripping away muscle control, strength, and everyday function. No disease-modifying therapy currently exists.
New data from the phase I/II ACHIEVE trial presented at the American Association of Neuromuscular and Electrodiagnostic Medicine meeting offer early but encouraging evidence that z-basivarsen may change that. The analysis pooled 26 DM1 patients treated across multiple doses and tracked them for 12 months. The primary muscle symptom — hand myotonia, or the inability to quickly relax a gripped hand — improved by a mean of 3.2 seconds from a baseline of 8.2 seconds, compared to a 0.4-second worsening in the placebo group.
Beyond myotonia, participants also showed sustained improvements in the 5 times sit-to-stand test, a widely used measure of lower-body functional strength, and in quantitative muscle testing scores. Patient-reported disease burden also improved. When compared against a natural history cohort of untreated DM1 patients, treated participants diverged favorably across every reported endpoint by month 12.
Z-basivarsen is an antisense oligonucleotide conjugated to an antibody fragment that targets the transferrin receptor, enabling muscle-cell entry. Once inside, it reduces toxic DMPK RNA, freeing splicing proteins to restore normal gene expression. The drug showed a favorable safety profile with no serious treatment-related adverse events, though infusion reactions, headache, and minor infections were reported.
Caveats are important: this is a small, early-phase trial without a randomized controlled comparison at the 12-month mark. Placebo comparisons relied on separate cohorts rather than a concurrent control arm. Larger phase III data will be needed to confirm efficacy and long-term safety before any regulatory application.
Key Findings
- Hand myotonia improved by 3.2 seconds over 12 months versus a 0.4-second worsening in the placebo group.
- Sit-to-stand performance and total muscle strength scores improved and were sustained through 12 months.
- Treated patients showed clear divergence from an untreated natural history cohort across all endpoints by one year.
- No serious drug-related adverse events were identified across 26 trial participants over 12 months.
- Z-basivarsen targets toxic DMPK RNA via an antisense mechanism, addressing the root molecular cause of DM1.
Methodology
This is a conference news report covering interim data from the phase I/II ACHIEVE trial, presented at a specialist neuromuscular medicine meeting. Evidence basis is early-phase clinical data from 26 patients with a pooled-dose design and comparisons to a natural history cohort rather than a concurrent randomized control arm. The source, MedPage Today, is a credible peer-reviewed medical news outlet; however, full peer-reviewed publication of these specific results has not been referenced.
Study Limitations
The 12-month comparison to a placebo group drew on a separate cohort from an earlier trial phase rather than a concurrent randomized arm, limiting causal inference. The sample size of 26 is small and may not capture the full safety or efficacy profile across the heterogeneous DM1 population. These data have not yet been published in a peer-reviewed journal, so full methodology and statistical details require independent verification.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: